Finding HPV Immune Targets for Future Cervical Cancer Vaccines in Adults
Studies blood and tumor samples from people with cervical cancer to find HPV targets.
Plain-language title generated from the registry record
Registry title: Discovery of HPV T Cell Epitopes and Development of Multi-epitope Vaccines
Key facts
- Where
- Hefei, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 to 65 with cervical cancer caused by HPV16 or HPV18, who can receive standard treatment.
- Age
- 18 to 65 years
- Sex
- Women only
- Disease stage
- Cervical cancer, pathological stage IB1 to IV, caused by HPV16 or HPV18 infection.
- Earlier treatment
- Must be able to receive standard treatment: surgery alone, or surgery followed by radiotherapy and chemotherapy.
- Biomarker or test result
- HPV16 or HPV18 infection.
Main reasons for not taking part
- Other cancers
- Uncontrolled systemic disease, such as active infection, uncontrolled high blood pressure or diabetes
- Unstable angina, congestive heart failure, or a heart attack within 1 year before starting treatment
- Severe arrhythmia needing medical treatment
- Blood clotting problems, or liver, kidney or metabolic disease
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07077980, who can take part
Where in China
- Anhui Provincal HospitalHefei, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Anhui Provincial Hospital
- Trial code
- NCT07077980
- Record updated
- 22 July 2025
- Original description
Based on the trend that the incidence and mortality of cervical carcinoma among female cancers worldwide are increasing year by year, the investigators aim to develop a multi-epitope therapeutic vaccine capable of simultaneously activating humoral and cellular immune responses, which is achieved by fusing multiple T-cell epitope immunostimulatory proteins. To obtain information on functional T-cell epitopes to be included in the vaccine, the investigators conducted research starting from clinical cases. By collecting peripheral blood and cancerous tissues from clinical patients, the investigators isolated reactive T-cells and screened for information on T-cell epitopes of HPV antigens.Read full original descriptionShow less
Discovery of HPV T Cell Epitopes and Development of Multi-epitope Vaccines
Based on the trend that the incidence and mortality of cervical carcinoma among female cancers worldwide are increasing year by year, the investigators aim to develop a multi-epitope therapeutic vaccine capable of simultaneously activating humoral and cellular immune responses, which is achieved by fusing multiple T-cell epitope immunostimulatory proteins. To obtain information on functional T-cell epitopes to be included in the vaccine, the investigators conducted research starting from clinical cases. By collecting peripheral blood and cancerous tissues from clinical patients, the investigators isolated reactive T-cells and screened for information on T-cell epitopes of HPV antigens.
Inclusion: Females aged between 18 and 65 who can receive standard treatment, including those who only undergo surgery or those who receive radiotherapy and chemotherapy after surgery; Cervical carcinoma caused by HPV16 or HPV18 infection; The pathological stage is from IB1 to IV, and informed consent is obtained; If the tumor tissue of patients with stage IB1 is not obvious, samples can be taken or not taken without affecting subsequent pathological examinations.
Exclusion: Patients with other malignancies; Patients with any uncontrolled systemic disease, including active infection, uncontrolled hypertension, diabetes mellitus, unstable angina and congestive heart failure, myocardial infarction (1 year) before starting treatment, severe arrhythmia requiring medical treatment, coagulation abnormalities, liver or kidney or metabolic disease.